Parathyroid growth and regression in experimental uremia

M. Taniguchi, M. Tokumoto, D. Matsuo, Kazuhiko Tsuruya, H. Hirakata, M. Iida

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Early 1,25-dihydroxyvitamin D3 (VD3) therapy during the course of renal failure prevents the downregulation of VD3 receptor (VDR), calcium-sensing receptor (CaSR) or p21, and the parathyroid (PT) growth. We hypothesized that VD3 could restore the decreased expressions of VDR and CaSR, and cause regression in enlarged PT glands. 5/6 nephrectomized rats fed high-phosphorus diet were killed at 1, 3, 5, or 7 days and at 2, 3, 4, 8, or 12 weeks. VD3-treated rats were given VD 3 intraperitoneally for 1, 2, 3, or 4 weeks, starting 8 weeks after 5/6 nephrectomy. PT glands were weighed and subjected to immunohistochemical analyses for VDR, CaSR, p21, Ki67, and Tdt-mediated dUTP nick end-labeling (TUNEL) assay. The area per cell was measured as the parameter of cell size. The expression of VDR and p21 began to decrease at day 1, and Ki67 increased at day 3, but decreased thereafter. There was a significant increase in PT gland weight to week 12 with the increase of cell size. VD3 treatment significantly increased both VDR and CaSR expressions 2 weeks after the start of injection, and reduced the PT gland weight at week 3 with significant increase of TUNEL-positive cells and decrease of cell size. Our results suggest that PT growth in uremic rats involves both PT cell proliferation and hypertrophy, in association with the reduction of VDR, CaSR, and p21 expressions. In addition, VD3 treatment could reverse PT hyperplasia and hypertrophy via restoration of these proteins.

Original languageEnglish
Pages (from-to)464-470
Number of pages7
JournalKidney International
Volume69
Issue number3
DOIs
Publication statusPublished - Feb 1 2006

Fingerprint

Calcium-Sensing Receptors
Calcitriol
Uremia
Parathyroid Glands
Cell Size
Growth
Hypertrophy
Weights and Measures
Calcitriol Receptors
Nephrectomy
Phosphorus
Hyperplasia
Renal Insufficiency
Therapeutics
Down-Regulation
Cell Proliferation
Diet
Injections
Proteins

All Science Journal Classification (ASJC) codes

  • Nephrology

Cite this

Taniguchi, M., Tokumoto, M., Matsuo, D., Tsuruya, K., Hirakata, H., & Iida, M. (2006). Parathyroid growth and regression in experimental uremia. Kidney International, 69(3), 464-470. https://doi.org/10.1038/sj.ki.5000090

Parathyroid growth and regression in experimental uremia. / Taniguchi, M.; Tokumoto, M.; Matsuo, D.; Tsuruya, Kazuhiko; Hirakata, H.; Iida, M.

In: Kidney International, Vol. 69, No. 3, 01.02.2006, p. 464-470.

Research output: Contribution to journalArticle

Taniguchi, M, Tokumoto, M, Matsuo, D, Tsuruya, K, Hirakata, H & Iida, M 2006, 'Parathyroid growth and regression in experimental uremia', Kidney International, vol. 69, no. 3, pp. 464-470. https://doi.org/10.1038/sj.ki.5000090
Taniguchi M, Tokumoto M, Matsuo D, Tsuruya K, Hirakata H, Iida M. Parathyroid growth and regression in experimental uremia. Kidney International. 2006 Feb 1;69(3):464-470. https://doi.org/10.1038/sj.ki.5000090
Taniguchi, M. ; Tokumoto, M. ; Matsuo, D. ; Tsuruya, Kazuhiko ; Hirakata, H. ; Iida, M. / Parathyroid growth and regression in experimental uremia. In: Kidney International. 2006 ; Vol. 69, No. 3. pp. 464-470.
@article{40669c432d294f729d5cf7a1e82b1de3,
title = "Parathyroid growth and regression in experimental uremia",
abstract = "Early 1,25-dihydroxyvitamin D3 (VD3) therapy during the course of renal failure prevents the downregulation of VD3 receptor (VDR), calcium-sensing receptor (CaSR) or p21, and the parathyroid (PT) growth. We hypothesized that VD3 could restore the decreased expressions of VDR and CaSR, and cause regression in enlarged PT glands. 5/6 nephrectomized rats fed high-phosphorus diet were killed at 1, 3, 5, or 7 days and at 2, 3, 4, 8, or 12 weeks. VD3-treated rats were given VD 3 intraperitoneally for 1, 2, 3, or 4 weeks, starting 8 weeks after 5/6 nephrectomy. PT glands were weighed and subjected to immunohistochemical analyses for VDR, CaSR, p21, Ki67, and Tdt-mediated dUTP nick end-labeling (TUNEL) assay. The area per cell was measured as the parameter of cell size. The expression of VDR and p21 began to decrease at day 1, and Ki67 increased at day 3, but decreased thereafter. There was a significant increase in PT gland weight to week 12 with the increase of cell size. VD3 treatment significantly increased both VDR and CaSR expressions 2 weeks after the start of injection, and reduced the PT gland weight at week 3 with significant increase of TUNEL-positive cells and decrease of cell size. Our results suggest that PT growth in uremic rats involves both PT cell proliferation and hypertrophy, in association with the reduction of VDR, CaSR, and p21 expressions. In addition, VD3 treatment could reverse PT hyperplasia and hypertrophy via restoration of these proteins.",
author = "M. Taniguchi and M. Tokumoto and D. Matsuo and Kazuhiko Tsuruya and H. Hirakata and M. Iida",
year = "2006",
month = "2",
day = "1",
doi = "10.1038/sj.ki.5000090",
language = "English",
volume = "69",
pages = "464--470",
journal = "Kidney International",
issn = "0085-2538",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Parathyroid growth and regression in experimental uremia

AU - Taniguchi, M.

AU - Tokumoto, M.

AU - Matsuo, D.

AU - Tsuruya, Kazuhiko

AU - Hirakata, H.

AU - Iida, M.

PY - 2006/2/1

Y1 - 2006/2/1

N2 - Early 1,25-dihydroxyvitamin D3 (VD3) therapy during the course of renal failure prevents the downregulation of VD3 receptor (VDR), calcium-sensing receptor (CaSR) or p21, and the parathyroid (PT) growth. We hypothesized that VD3 could restore the decreased expressions of VDR and CaSR, and cause regression in enlarged PT glands. 5/6 nephrectomized rats fed high-phosphorus diet were killed at 1, 3, 5, or 7 days and at 2, 3, 4, 8, or 12 weeks. VD3-treated rats were given VD 3 intraperitoneally for 1, 2, 3, or 4 weeks, starting 8 weeks after 5/6 nephrectomy. PT glands were weighed and subjected to immunohistochemical analyses for VDR, CaSR, p21, Ki67, and Tdt-mediated dUTP nick end-labeling (TUNEL) assay. The area per cell was measured as the parameter of cell size. The expression of VDR and p21 began to decrease at day 1, and Ki67 increased at day 3, but decreased thereafter. There was a significant increase in PT gland weight to week 12 with the increase of cell size. VD3 treatment significantly increased both VDR and CaSR expressions 2 weeks after the start of injection, and reduced the PT gland weight at week 3 with significant increase of TUNEL-positive cells and decrease of cell size. Our results suggest that PT growth in uremic rats involves both PT cell proliferation and hypertrophy, in association with the reduction of VDR, CaSR, and p21 expressions. In addition, VD3 treatment could reverse PT hyperplasia and hypertrophy via restoration of these proteins.

AB - Early 1,25-dihydroxyvitamin D3 (VD3) therapy during the course of renal failure prevents the downregulation of VD3 receptor (VDR), calcium-sensing receptor (CaSR) or p21, and the parathyroid (PT) growth. We hypothesized that VD3 could restore the decreased expressions of VDR and CaSR, and cause regression in enlarged PT glands. 5/6 nephrectomized rats fed high-phosphorus diet were killed at 1, 3, 5, or 7 days and at 2, 3, 4, 8, or 12 weeks. VD3-treated rats were given VD 3 intraperitoneally for 1, 2, 3, or 4 weeks, starting 8 weeks after 5/6 nephrectomy. PT glands were weighed and subjected to immunohistochemical analyses for VDR, CaSR, p21, Ki67, and Tdt-mediated dUTP nick end-labeling (TUNEL) assay. The area per cell was measured as the parameter of cell size. The expression of VDR and p21 began to decrease at day 1, and Ki67 increased at day 3, but decreased thereafter. There was a significant increase in PT gland weight to week 12 with the increase of cell size. VD3 treatment significantly increased both VDR and CaSR expressions 2 weeks after the start of injection, and reduced the PT gland weight at week 3 with significant increase of TUNEL-positive cells and decrease of cell size. Our results suggest that PT growth in uremic rats involves both PT cell proliferation and hypertrophy, in association with the reduction of VDR, CaSR, and p21 expressions. In addition, VD3 treatment could reverse PT hyperplasia and hypertrophy via restoration of these proteins.

UR - http://www.scopus.com/inward/record.url?scp=31544438582&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=31544438582&partnerID=8YFLogxK

U2 - 10.1038/sj.ki.5000090

DO - 10.1038/sj.ki.5000090

M3 - Article

C2 - 16395258

AN - SCOPUS:31544438582

VL - 69

SP - 464

EP - 470

JO - Kidney International

JF - Kidney International

SN - 0085-2538

IS - 3

ER -